Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

This case report describes a 50-year-old woman with palmoplantar psoriasis who developed alopecia areata after starting tildrakizumab, suggesting a possible paradoxical reaction related to the medication.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.